Pushing healthcare forward requires us to propel medicines to their full potential. We make possible what others consider impossible. Take a look at our product portfolio to see what the right mix of technology and heart can accomplish.
RYANODEX® is indicated for the treatment of malignant hyperthermia in conjunction with appropriate supportive measures, and for the prevention of malignant hyperthermia in patients at high risk.1
Docetaxel Injection is a microtubule inhibitor indicated for3:
Breast Cancer (BC): single agent for locally advanced or metastatic BC after chemotherapy failure; and with doxorubicin and cyclophosphamide as adjuvant treatment of operable node-positive BC
Non-Small Cell Lung Cancer (NSCLC): single agent for locally advanced or metastatic NSCLC after platinum therapy failure; and with cisplatin for unresectable, locally advanced or metastatic untreated NSCLC
Hormone Refractory Prostate Cancer (HRPC): with prednisone in androgen independent (hormone refractory) metastatic prostate cancer
Gastric Adenocarcinoma (GC): with cisplatin and fluorouracil for untreated, advanced GC, including the gastroesophageal junction
Squamous Cell Carcinoma of the Head and Neck Cancer (SCCHN): with cisplatin and fluorouracil for induction treatment of locally advanced SCCHN
BENDEKA® is an alkylating drug indicated for the treatment of patients with2:
Argatroban Injection is a direct thrombin inhibitor indicated4:
Identify medicines that can benefit from second generation advancements
Improve products by determining the technology requirements to address unmet needs
Impact patients’ lives with improved medicines brought to market primarily through the 505(b)(2) regulatory pathway
Through a fully integrated commercial team, we have the flexibility to market our products with or without a partner.